[{"orgOrder":0,"company":"Stablepharma","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"SPVX02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stablepharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stablepharma \/ EIC Accelerator","highestDevelopmentStatusID":"5","companyTruncated":"Stablepharma \/ EIC Accelerator"}]

Find Clinical Drug Pipeline Developments & Deals by Stablepharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The grant comes as the company will move forward to accelerated the clinical trials for its lead candidate, SPVX02, a fridge-free tetanus and diphtheria vaccine.

                          Product Name : SPVX02

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          February 19, 2025

                          Lead Product(s) : SPVX02

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : EIC Accelerator

                          Deal Size : $2.6 million

                          Deal Type : Funding

                          blank